Antagonistic TNF receptor one-specific antibody (ATROSAB): Receptor binding and in vitro bioactivity

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Richter, Fabian ^a   Liebig, Timo ^b   Guenzi, Eric ^c   Herrmann, Andreas ^c   Scheurich, Peter ^a   Pfizenmaier, Klaus ^a   Kontermann, Roland E ^a  

^a UNIVERSITY OF STUTTGART   (Germany)

^b Celonic AG   (Switzerland)

^c Baliopharm   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ATROSAB; CD16 ANTIGEN; COMPLEMENT COMPONENT C1Q; FC RECEPTOR; FC RECEPTOR IIB; HISTIDINE; I KAPPA B ALPHA; IMMUNOGLOBULIN G1 ANTIBODY; INTERLEUKIN 6; INTERLEUKIN 8; LYMPHOTOXIN; RITUXIMAB; TRASTUZUMAB; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN; UNCLASSIFIED DRUG; IL6 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PROTEIN BINDING; TUMOR NECROSIS FACTOR ALPHA;

AMINO TERMINAL SEQUENCE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CELL SURVIVAL; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT FIXATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOLYSIS; DRUG ANTAGONISM; EFFECTOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FLOW CYTOMETRY; GEL PERMEATION CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; QUARTZ CRYSTAL MICROBALANCE; RECEPTOR BINDING; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CHEMICAL STRUCTURE; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; KINETICS; METABOLISM; MOLECULAR GENETICS; MOUSE; PROTEIN TERTIARY STRUCTURE; SECRETION (PROCESS); TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL LINE, TUMOR; COMPLEMENT C1Q; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; KINETICS; LYMPHOTOXIN-ALPHA; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, IGG; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84886095507     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072156     Document Type: Article

References (65)

1. Schall TJ, Lewis M, Koller KJ, Lee A, Rice GC, et al. (1990) Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell 61: 361-370
2. Loetscher H, Pan YC, Lahm HW, Gentz R, Brockhaus M, et al. (1990) Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell 61: 351-359
3. Himmler A, Maurer-Fogy I, Kronke M, Scheurich P, Pfizenmaier K, et al. (1990) Molecular cloning and expression of human and rat tumor necrosis factor receptor chain (p60) and its soluble derivative, tumor necrosis factor-binding protein. DNA Cell Biol 9: 705-715
4. Locksley RM, Killeen N, Lenardo MJ (2001) The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104: 487-501
5. Cabal-Hierro L, Lazo PS (2012) Signal transduction by tumor necrosis factor receptors. Cell Signal. 24: 1297-1305
6. Wajant H, Pfizenmaier K, Scheurich P (2003) Tumor necrosis factor signaling. Cell Death Differ 10: 45-65
7. Grell M, Douni E, Wajant H, Lohden M, Clauss M, et al. (1995) The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83: 793-802
8. Fontaine V, Mohand-Said S, Hanoteau N, Fuchs C, Pfizenmaier K, et al. (2002) Neurodegenerative and neuroprotective effects of tumor Necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2. J Neurosci 22: RC216
9. Goukassian DA, Qin G, Dolan C, Murayama T, Silver M, et al. (2007) Tumor necrosis factor-Alpha receptor p75 is required in ischemia-induced neovascularization. Circulation 115: 752-762
10. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117: 244-279
11. Kontermann RE, Scheurich P, Pfizenmaier K (2009) Antagonists of TNF action -clinical experience and new developments. Expert Opin Drug Discov 4: 279-292
12. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, et al. (2006) Anti- TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-Analysis of rare harmful effects in randomized controlled trials. JAMA 295: 2275-2285
13. Desai SB, Furst DE (2006) Problems encountered during anti-Tumour necrosis factor therapy. Best Pract Res Clin Rheumatol. 20: 757-790
14. Wallis RS (2008) Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 8: 601-611
15. Rosenblum H, Amital H (2011) Anti-TNF therapy: safety aspects of taking the risk. Autoimmun Rev 10: 563-568
16. Zidi I, Bouaziz A, Mnif W, Bartegi A, Ben Amor N (2011) Golimumab and malignancies: true or false association? Med Oncol 28: 641-648
17. Shakoor N, Michalska M, Harris CA, Block JA (2002) Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359: 579-580
18. de Gannes GC, Ghoreishi M, Pope J, Russell A, Bell D, et al. (2007) Psoriasis and pustular dermatitis triggered by TNF-A inhibitors in patients with rheumatologic conditions. Arch Dermatol 143: 223-231
19. Ramos-Casals M, Brito-Zeron P, Munoz S, Soria N, Galiana D, et al. (2007) Autoimmune diseases induced by TNF-Targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86: 242-251
20. Tack CJ, Kleijwegt FS, Van Riel PL, Roep BO (2009) Development of type 1 diabetes in a patient treated with anti-TNF-Alpha therapy for active rheumatoid arthritis. Diabetologia 52: 1442-1444
21. Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, et al. (2001) TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat. Neurosci 4: 1116-1122
22. Kassiotis G, Kollias G (2001) Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J. Exp. Med. 193, 427-434
23. Van Hauwermeiren F, Vandenbroucke RE, Libert C (2011) Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFR1. Cytokine Growth Factor Rev 22: 311-319
24. Shibata H, Yoshioka Y, Ohkawa A, Abe Y, Nomura T, et al. (2008) The therapeutic effect of TNFR1-selective antagonistic mutant TNF-Alpha in murine hepatitis models. Cytokine 44: 229-233
25. Shibata H, Yoshioka Y, Abe Y, Ohkawa A, Nomura T, et al. (2009) The treatment of established murine collagen-induced arthritis with a TNFR1- selective antagonistic mutant TNF. Biomaterials 30: 6638-6647
26. Nomura T, Abe Y, Kamada H, Shibata H, Kayamuro H, et al. (2011) Therapeutic effect of PEGylated TNFR1-seletive antagonistic mutant TNF in experimental autoimmune encephalomyelitis mice. J Control Release 149: 8-14
27. Kitagaki M, Isoda K, Kamada H, Kobayashi T, Tsunoda S, et al. (2012) Novel TNF-A receptor 1 antagonist treatment attenuates arterial inflammation and intimal hyperplasia in mice. J Atheroscler Thromb 19: 36-40
28. Zalevsky J, Secher T, Ezhevsky SA, Janot L, Steed PM, et al. (2007) Dominantnegative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. J Immunol 179: 1872-1883
29. Olleros ML, Vesin D, Lambou AF, Janssens JP, Ryffel B, et al. (2009) Dominant-negative tumor necrosis factor protects from Mycobacterium bovis Bacillus Calmette Guerin (BCG) and endotoxin-induced liver injury without compromising host immunity to BCG and Mycobacterium tuberculosis. J Infect Dis 199: 1053-1063
30. Perrier C, de Hertogh G, Cremer J, Vermeire S, Rutgeerts P, et al. (2013) Neutralization of membrane TNF, but not soluble TNF, is crucial for the treatment of experimental colitis. Inflamm Bowel Dis 19: 246-253
31. Arntz OJ, Geurts J, Veenbergen S, Bennink MB, van den Brand BT, et al. (2010) A crucial role for tumor necrosis factor receptor 1 in synovial lining cells and the reticuloendothelial system in mediating experimental arthritis. Arthritis Res Ther 12: R61
32. Huang XW, Yang J, Dragovic AF, Zhang H, Lawrence TS, et al. (2006) Antisense oligonucleotide inhibition of tumor necrosis factor receptor 1 protects the liver from radiation-induced apoptosis. Clin Cancer Res 12: 2849-2855
33. Thoma B, Grell M, Pfizenmaier K, Scheurich P (1990) Identification of a 60-kD tumor necrosis factor (TNF) receptor as the major signal transducing component in TNF responses. J Exp Med 172: 1019-1023
34. Kruppa G, Thoma B, Machleidt T, Wiegmann K, Kronke M (1992) Inhibition of tumor necrosis factor (TNF)-mediated NF-kappa B activation by selective blockade of the human 55-kDa TNF receptor. J Immunol 148: 3152-3157
35. Moosmayer D, Dubel S, Brocks B, Watzka H, Hampp C, et al. (1995) A singlechain TNF receptor antagonist is an effective inhibitor of TNF mediated cytotoxicity. Ther Immunol 2: 31-40
36. Kontermann RE, Munkel S, Neumeyer J, Muller D, Branschadel M, et al. (2008) A humanized tumor necrosis factor receptor 1 (TNFR1)-specific antagonistic antibody for selective inhibition of tumor necrosis factor (TNF) action. J Immunother 31: 225-234
37. Zettlitz KA, Lorenz V, Landauer K, Munkel S, Herrmann A, et al. (2010) ATROSAB, a humanized antagonistic anti-Tumor necrosis factor receptor onespecific antibody. MAbs 2: 639-647
38. Armour KL, Clark MR, Hadley AG, Williamson LM (1999) Recombinant human IgG molecules lacking Fcc receptor I binding and monocyte triggering activities. Eur J Immunol 29: 2613-2624
39. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, et al. (2009) Specificity and affinity of human Fcc receptors and their polymorphic variants for human IgG subclasses. Blood 113: 3716-3725
40. Moore GL, Chen H, Karki S, Lazar GA (2010) Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. MAbs 2: 181-189
41. Grell M, Scheurich P, Meager A, Pfizenmaier K (1993) TR60 and TR80 tumor necrosis factor (TNF)-receptors can independently mediate cytolysis. Lymphokine Cytokine Res 12: 143-148
42. Brockhaus M, Schoenfeld HJ, Schlaeger EJ, Hunziker W, Lesslauer W, et al. (1990) Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci USA 87: 3127-3131
43. Espevik T, Brockhaus M, Loetscher H, Nonstad U, Shalaby R (1990) Characterization of binding and biological effects of monoclonal antibodies against a human tumor necrosis factor receptor. J Exp Med 171: 415-426
44. Banner DW, D'Arcy A, Janes W, Gentz R, Schoenfeld HJ, et al. (1993) Crystal structure of the soluble human 55 kd TNF receptor-human TNFb complex: implications for TNF receptor activation. Cell 73: 431-445
45. Li F, Ravetch JV (2012) A general requirement of FccRIIB co-engagement of agonistic anti-TNFR antibodies. Cell Cycle 11: 3343-3344
46. Nygren H, Czerkinsky C, Stenberg M (1985) Dissociation of antibodies bound to surface-immobilized antigen. J Immunol Methods 85: 87-95
47. Kaufman EN, Jain RK (1992) Effect of bivalent interaction upon apparent antibody affinity: experimental confirmation of theory using fluorescence photobleaching and implications for antibody binding assays. Cancer Res 52: 4157-4167
48. Grell M, Wajant H, Zimmermann G, Scheurich P (1998) The type 1 receptor (CD120a) is the high affinity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci USA 95: 570-575
49. Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL, et al. (2000) A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 288: 2351-2354
50. Legler DF, Micheau O, Doucey MA, Tschopp J, Bron C (2003) Recruitment of TNF receptor 1 to lipid rafts is essential for TNFa-mediated NFkB activation. Immunity 18: 655-664
51. Ranzinger J, Krippner-Heidenreich A, Haraszti T, Bock E, Tepperink J, et al. (2009) Nanoscale arrangement of apoptotic ligands reveals a demand for a minimal lateral distance for efficient death receptor activation. Nano Lett 9: 4240-4245
52. Gerken M, Krippner-Heidenreich A, Steinert S, Willi S, Neugart F, et al. (2010) Fluorescence correlation spectroscopy reveals topological segregation of the two tumor necrosis factor membrane receptors. Biochim Biophys Acta 1798: 1081-1089
53. Branschadel M, Aird A, Zappe A, Tietz C, Krippner-Heidenreich A, et al. (2010) Dual function of cysteine rich domain (CRD) 1 of TNF receptor type 1: conformational stabilization of CRD2 and control of receptor responsiveness. Cell Signal 22: 404-414
54. Winkel C, Neumann S, Surulescu C, Scheurich P (2012) A minimal mathematical model for the initial molecular interactions of death receptor signalling. Math Biosci Eng 9: 663-683
55. Krippner-Heidenreich A, Tubing F, Bryde S, Willi S, Zimmermann G, et al. (2002) Control of receptor-induced signaling complex formation by the kinetics of ligand/receptor interaction. J Biol Chem 277: 44155-44163
56. Lewis AK, Valley CC, Sachs JN (2012) TNFR1 signaling is associated with backbone conformational changes of receptor dimers consistent with overactivation in the R92Q TRAPS mutant. Biochemistry 551: 6546-6555
57. Telliez JB, Xu GY, Woronicz JD, Hsu S, Wu JL, et al. (2000) Mutational analysis and NMR studies of the death domain of the tumor necrosis factor receptor-1. J Mol Biol 300: 1323-1333
58. Sukits SF, Lin LL, Hsu S, Malakian K, Powers R, et al. (2001) Solution structure of the tumor necrosis factor receptor-1 death domain. J Mol Biol 310: 895-906
59. Calmon-Hamaty F, Combe B, Hahne M, Morel J (2011) Lymphotoxin a revisted: general features and implications in rheumatoid arthritis. Arthritis Res 13: 232
60. Ruddle NH, Steinman L (1990) Lymphotoxin and tumor necrosis factor-Alpha production by myelin basic protein-specific T cell clones correlates with encephalitogenicity. Int Immunol 2: 539-544
61. Suen WE, Bergman CM, Hjelmstrom P, Ruddle NH (1997) A critical role of lymphotoxin in experimental allergic encephalomyelitis. J Exp Med 186: 1233-1240
62. Chiang EY, Kolumam GA, Yu X, Francesco M, Ivelja S, et al. (2009) Targeted depletion of lymphotoxin-A-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat Med 15: 766-773
63. Buch MH, Conaghan PG, Quinn MA, Bingham SJ, Veale D, et al. (2004) True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin a? Ann Rheum Dis 63: 1344-1346
64. Grell M, Zimmermann G, Hulser D, Pfizenmaier K, Scheurich P (1994) TNF receptors TR60 and TR80 can mediate apoptosis via induction of distinct signal pathways. J Immunol 153: 1963-1972
65. Carter PH, Scherle PA, Muckelbauer JA, Voss ME, Liu RQ, et al. (2001) Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-A. Proc Natl Acad Sci USA 98: 11879-11884